Lancet: Pym monoantial combination chemotherapy first-line treatment of PD-L1-positive metastasis triple negative breast cancer

The use of Pembrolizumab alone showed long-lasting anti-tumor activity and controllable safety in patients with metastasis triple-negative breast cancer.
recently examined the efficacy of Pym monoantial combination chemotherapy in patients with metastasis triple negative breast cancer.
The study was conducted at 209 medical centers in 29 countries for randomized, controlled, double-blind studies involving patients with untreated local recurrence of non-surgical or metastasis triple negative breast cancer in chemotherapy (albumin yew alcohol, yew alcohol or gissie On the basis of 200 mg of Pim monoantigen or placebo every 3 weeks, PD-L1 expression (CPS score <1 or ≥1) and previous new complementary treatment options were layered according to the chemotherapy program.
end point of the study was no progress and total lifetime.
847 patients were treated, of whom 566 received Pim monoantin and 281 received a placebo.
in the second interim analysis (11 December 2019), the Pym monoantial group followed for an average of 25.9 months and the placebo group followed for 26.3 months.
For patients with a CPS score of more than 10, the progression-free survival of the Pym monoantial group was 9.7 months and the placebo group was 5.6 months (disease progression or death HR=0.65), but for all patients with a CPS score of 1 or higher, the progression-free survival period was 7.6 months and 5.6 months, respectively.
68% of patients in the Pym monoantiatress group had adverse events associated with treatment at level 3-5, 67% in the placebo group, less than 1% of patients in the Pham monoants group died from adverse events, and no patients in the placebo group died from adverse events.
study concluded that for patients with metastasis triple negative breast cancer with CPS score of more than 10, Pim monoantial combination chemotherapy can significantly improve the progressive survival, Pim monoantial can be used as a high expression of PD-L1 metastasis triple negative breast cancer patients first-line treatment.
。